Literature DB >> 28491945

Reference values for T, B and NK human lymphocyte subpopulations in adults.

P A Apoil1,2, B Puissant-Lubrano1,2, N Congy-Jolivet1,2, M Peres2, J Tkaczuk2, F Roubinet3, A Blancher1,2.   

Abstract

The data presented in this paper are reference ranges for frequencies of thirty-eight subpopulations of T, B and NK lymphocytes, established from a cohort of 253 healthy blood donors aged from 19 to 67. When relevant, the influence of age or sex was taken into account to calculate these reference values. This article is related to the research article entitled "Influence of age, sex and HCMV-serostatus on blood lymphocyte subpopulations in healthy adults" (Apoil et al., 2017) [1]. Immunophenotyping data obtained from each individual is made publicly available for extended analyses.

Entities:  

Keywords:  Age; Immunophenotyping; Lymphocyte subpopulations; Reference ranges; Sex

Year:  2017        PMID: 28491945      PMCID: PMC5415546          DOI: 10.1016/j.dib.2017.04.019

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data Reference values of 38 distinct subpopulations of T, B and NK lymphocytes were established through the study of a large population sample of healthy adults, in accordance with CLSI standards. These reference values are adequate for interpreting clinical laboratory results from young adults and middle-aged patients. Low- frequency subpopulations (T cells expressing intermediate levels of CD4 or CD8 molecules or positive for NK-related markers) were included in this study. Reference ranges were adjusted for age or sex when these parameters impact the values.

Data

Data in the following Tables present the reference values for 38 distinct human T, B or NK lymphocyte subpopulations. When sex or age has a significant impact on these subpopulations, separate reference values are given for male, female, younger (19–44) or older (45–67) individuals. Data are expressed either as absolute numbers of cells in G/L (a), or as the percentage of cells relative to total CD3+ (b), CD3+ CD4+ (c), CD3+ CD8+ (d) T lymphocytes, Tregs (e), total B (f) or NK cells (g); DN: CD4-CD8- double-negative T cells; DP: CD4+CD8+ double-positive T cells.

Experimental design, materials and methods

Cohort assembly

Healthy blood donors aged 19–67 (median age 44 y.o.) were recruited between 2011 and 2013 in Toulouse (Etablissement Français du Sang Pyrénées-Méditerranée, Southwest of France). All subjects were negative in serological tests for blood-transmissible infections (HIV, hepatitis B and C, HTLV, syphilis) and were exempt from any pathology or treatment which could interfere with leukocyte parameters (history of cancer or of autoimmune disease, active or recent systemic infection, immunosuppressive or immunomodulating therapy, severe allergy, or a vaccine administered less than 3 months ago). For each enrolled blood donor, a single 7 mL EDTA tube of peripheral whole blood was collected between 8 a.m. and 11 a.m. Reference values were calculated from a cohort of 253 individuals, adjusted for sex ratio and frequency of HCMV-seropositivity, which was made from a larger cohort of 283 blood donors (complete immunophenotyping data for these 283 individuals is presented in Appendix A: Supplementary material). Details about the composition of this cohort are available online in Supplementary material from [1].

Immunophenotyping and cytometry data analysis

Immunophenotyping was performed by multicolour flow cytometry: samples were labeled with 4 distinct antibody panels and absolute counts of T, B and NK cells were determined by using BD Trucount® tubes. Cytometric data was acquired on a BD CANTO II® flow cytometer (BD Biosciences, Le Pont De Claix, France) and was analyzed with BD Diva and FlowJo® software (LLC, Ashland, OR). Antibody panels and gating strategies are detailed in Ref. [1]. Mean values and reference ranges were calculated according to CLSI guidelines [2] (including suspected outliers in the calculation) by using the Reference Value Advisor software [3], from the entire population sample, or from subgroups of more than 120 individuals (males/females and younger/older). To evaluate the influence of age and sex, Mann–Whitney non-parametric tests were carried-out after removal of outliers, and the corrected ranges are indicated when p<0.05.

Funding sources

This work was supported by Paul Sabatier University (Toulouse, France), Région Midi-Pyrénées and by the French Ministry of Higher Education and Research.
Subject areaBiology
More specific subject areaHuman Immunology
Type of dataTables
How data was acquiredImmunophenotyping by multicolour flow cytometry
Data formatReference values for human lymphocytes are presented as percentages (for subpopulations) or absolute counts (all T lymphocytes, T CD4+, T CD8+, B and NK cells); counts and subpopulation frequencies for each blood donor are communicated as a transparency document.
Experimental factorsPeripheral whole blood anticoagulated with EDTA
Experimental featuresSamples were labeled with 4 distinct antibody panels: four 8-colour panels were used to study subpopulation frequencies and a 4-colour panel was dedicated to absolute counts; reference values were calculated in accordance with the Clinical and Laboratory Standards Institute (CLSI) recommendations. Non-parametric Mann-Whitney test was used to evaluate the impact of age and sex on these subpopulations.
Data source locationToulouse, Midi-Pyrénées, France
Data accessibilityThe data are available in this article
Sub-population(T lymphocytes)Allmean(ref. values)Malesmean(ref. values)Femalesmean(ref. values)Age≤44mean(ref. values)Age>44mean(ref. values)
CD3+ (a)1473(700–2508)1387(675–2491)1560(787–2533)1545(783–2532)1412(699–2213)
CD3+ CD4+ CD8− (a)928(464–1721)841(394–1620)1017(573–1815)no influence of age
CD3+ CD4− CD8+(a)405(135–852)no influence of sex441(157–881)370(131–825)
CD4+/CD8+ ratio2.6(1–6.2)2.4(1–6)2.7(1–6.7)2.3(0.9–4.2)2.9(1–6.7)
CD3+ CD4+ CD8+ DP (b)0.4%(0.09–1.65)0.3%(0.07–1.1)0.5%(0.1–2)no influence of age
CD3+ CD4− CD8− DN (b)7%(1.7–21.4)8.3%(1.8–27.8)5.6%(1.5–14.9)8.2%(2.2–25)5.8%(1.4–20.3)
CD3+ CD4− CD8low (b)2.9%(1.05–5.9)3.3%(1.41–6.6)2.6%(1–4.7)no influence of age
CD3+ CD4+ CD8low (b)0.3%(0.05–1.6)no influence of sex0.3%(0.05–1.6)0.3%(0.05–1.6)
CD4+ Naïve (c)(62L+ 45RA+ 27+ 28+)43.1%(17.8–66.3)no influence of sex46.3%(19.9–67.8)39.8%(14.4–65.2)
CD4+ Central memory (c)(62L+ 45RA− 27+ 28+)32.8%(19.4–51.9)no influence of sex33.9%(7.6–62.5)31.3%(15.3–52.8)
CD4+ Effector memory (c)(62L− 45RA+/− 27+/− 28+)16.7%(7.4–31.9)17.8%(8–33.7)15.6%(6.7–27.7)16%(6.7–28.5)17.5%(8–35.3)
CD4+ EMRA (c)(62L− 45RA+ 27−28−)1.6%(<0.01–14)no influence of sex0.1%(0–2)3.4%(0–22.4)
CD8+ Naïve (d)(62L+ 45RA+ 27+ 28+)36%(7.5–66.8)no influence of sex40.6%(6–73.4)30.2%(1.5–65.5)
CD8+ Central memory (d)(62L+ 45RA− 27+ 28+)9.6%(3.4–22.4)no influence of sex8.1%(3.4–16.8)11%(3.5–28.6)
CD8+ Effector memory 27+(62L− 45RA− 27+ 28+/−) (d)18.9%(6–38.9)no influence of sex17.3%(5.4–34.4)20.5%(6–43.4)
CD8+ Effector memory 27-(62L− 45RA− 27− 28+/−) (d)4.7%(0.4–19)no influence of sex3.2%(0–23.9)6.6%(0.7–72.6)
CD8+ EMRA pE1+pE2(62L− 45RA+ 27+28+/−) (d)8.6%(2.5–21.2)9.3%(2.1–22.2)7.8%(2.5–18.3)7.6%(2.4–16.5)9.5%(2.5–22.4)
CD8+ EMRA (d)(62L− 45RA+ 27− 28−)9.9%(0.3–32.2)no influence of sex4.7%(0.1–37.5)16.5%(1.6–52.5)
Tregs (c)(4+ CCR4+ 45RA− 127− 25++)2.9%(1.3–5.5)no influence of sex2.7%(1.4–5.1)3.2%(1.0–5.8)
HLA-DR+ Tregs (e)(Tregs HLA-DR+)26%(10.3–43.1)no influence of sex24.4%(9.7–38.3)28%(10.1–49)
HLA-DR+ CD4+ memory(c)(4+ 45RA− HLA-DR+)3.2%(0.9–7.7)no influence of sex2.9%(0.9–6.3)3.5%(0.8–8.2)
HLA-DR+ CD8+ memory(d)(8+ 45RA− HLA-DR+)10.2%(2.9–25.4)no influence of sexno influence of age
CD3+ NKB1− NKp30+ (b)0.5%(0–4.4)0.4%(0–4.3)0.5%(0–5.1)0.4%(0–2.2)0.5%(0–3.4)
CD3+ 56+ (b)5.5%(1.1–14.9)no influence of sexno influence of age
CD3+ 16+ (b)2.4%(0.3–8.1)no influence of sex2.8%(0.3–9.9)2%(0.3–7)
  2 in total

1.  Reference Value Advisor: a new freeware set of macroinstructions to calculate reference intervals with Microsoft Excel.

Authors:  Anne Geffré; Didier Concordet; Jean-Pierre Braun; Catherine Trumel
Journal:  Vet Clin Pathol       Date:  2011-02-07       Impact factor: 1.180

2.  Influence of age, sex and HCMV-serostatus on blood lymphocyte subpopulations in healthy adults.

Authors:  P A Apoil; B Puissant-Lubrano; N Congy-Jolivet; M Peres; J Tkaczuk; F Roubinet; A Blancher
Journal:  Cell Immunol       Date:  2017-02-09       Impact factor: 4.868

  2 in total
  13 in total

1.  An optimized five-color/seven-parameter flow cytometry panel for immunophenotyping guinea pig peripheral blood lymphocytes.

Authors:  John V Stokes; Anna E Crawford; Claire E Cross; Anne-Marie L Ross; Jamie D Walker; Bridget V Willeford; Andrea S Varela-Stokes
Journal:  J Immunol Methods       Date:  2019-11-01       Impact factor: 2.303

2.  CyTOF Measurement of Immunocompetence Across Major Immune Cell Types.

Authors:  Priyanka B Subrahmanyam; Holden T Maecker
Journal:  Curr Protoc Cytom       Date:  2017-10-02

Review 3.  The guinea pig model for tick-borne spotted fever rickettsioses: A second look.

Authors:  John V Stokes; David H Walker; Andrea S Varela-Stokes
Journal:  Ticks Tick Borne Dis       Date:  2020-08-07       Impact factor: 3.744

4.  Complex Muco-cutaneous Manifestations of CARMIL2-associated Combined Immunodeficiency: A Novel Presentation of Dysfunctional Epithelial Barriers.

Authors:  Giuseppe Marangi; Simone Garcovich; Gabriele Di Sante; Daniela Orteschi; Silvia Frangella; Franco Scaldaferri; Maurizio Genuardi; Ketty Peris; Fiorella Gurrieri; Marcella Zollino
Journal:  Acta Derm Venereol       Date:  2020-01-23       Impact factor: 3.875

5.  Immune Defect in Adults With Down Syndrome: Insights Into a Complex Issue.

Authors:  Yannick Dieudonné; Beatrice Uring-Lambert; Mohamed Maxime Jeljeli; Vincent Gies; Yves Alembik; Anne-Sophie Korganow; Aurélien Guffroy
Journal:  Front Immunol       Date:  2020-05-08       Impact factor: 7.561

6.  Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.

Authors:  Henna Kasanen; Micaela Hernberg; Siru Mäkelä; Oscar Brück; Susanna Juteau; Laura Kohtamäki; Mette Ilander; Satu Mustjoki; Anna Kreutzman
Journal:  Cancer Immunol Immunother       Date:  2020-02-08       Impact factor: 6.968

7.  Blood CD3-(CD56 or 16)+ natural killer cell distributions are heterogeneous in healthy adults and suppressed by azathioprine in patients with ANCA-associated vasculitides.

Authors:  Wolfgang Merkt; Ulrich Salzer; Jens Thiel; Ilona Jandova; Raoul Bergner; Ana C Venhoff; Nils Venhoff
Journal:  BMC Immunol       Date:  2021-04-12       Impact factor: 3.615

8.  Chronic demodicosis in patients with immune dysregulation: An unexpected infectious manifestation of Signal transducer and activator of transcription (STAT)1 gain-of-function.

Authors:  Oded Shamriz; Atar Lev; Amos J Simon; Ortal Barel; Elisheva Javasky; Sigal Matza-Porges; Adir Shaulov; Zev Davidovics; Ori Toker; Raz Somech; Abraham Zlotogorski; Vered Molho-Pessach; Yuval Tal
Journal:  Clin Exp Immunol       Date:  2021-07-12       Impact factor: 5.732

9.  Establishment of normative ranges of the healthy human immune system with comprehensive polychromatic flow cytometry profiling.

Authors:  John S Yi; Marilyn Rosa-Bray; Janet Staats; Pearl Zakroysky; Cliburn Chan; Melissa A Russo; Chelsae Dumbauld; Scott White; Todd Gierman; Kent J Weinhold; Jeffrey T Guptill
Journal:  PLoS One       Date:  2019-12-11       Impact factor: 3.240

10.  Monogenic Inflammatory Bowel Disease: It's Never Too Late to Make a Diagnosis.

Authors:  Iddo Vardi; Irit Chermesh; Lael Werner; Ortal Barel; Tal Freund; Collin McCourt; Yael Fisher; Marina Pinsker; Elisheva Javasky; Batia Weiss; Gideon Rechavi; David Hagin; Scott B Snapper; Raz Somech; Liza Konnikova; Dror S Shouval
Journal:  Front Immunol       Date:  2020-09-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.